Search Results - "Ataulfo Gonzalez, F"

Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor–experienced adult patients with PNH: the 302 study by Kulasekararaj, Austin G., Hill, Anita, Rottinghaus, Scott T., Langemeijer, Saskia, Wells, Richard, Gonzalez-Fernandez, F. Ataulfo, Gaya, Anna, Lee, Jong Wook, Gutierrez, Emilio Ojeda, Piatek, Caroline I., Szer, Jeff, Risitano, Antonio, Nakao, Shinji, Bachman, Eric, Shafner, Lori, Damokosh, Andrew I., Ortiz, Stephan, Röth, Alexander, Peffault de Latour, Regis

“…Ravulizumab, a new complement component C5 inhibitor administered every 8 weeks, was noninferior to eculizumab administered every 2 weeks in…”
Get full text

Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria by Peipert, John Devin, Kulasekararaj, Austin G., Gaya, Anna, Langemeijer, Saskia M. C., Yount, Susan, Gonzalez-Fernandez, F. Ataulfo, Ojeda Gutierrez, Emilio, Martens, Christa, Sparling, Amy, Webster, Kimberly A., Cella, David, Tomazos, Ioannis, Ogawa, Masayo, Piatek, Caroline I., Wells, Richard, Sicre de Fontbrune, Flore, Röth, Alexander, Mitchell, Lindsay, Hill, Anita, Kaiser, Karen

“…Background Eculizumab has transformed management of paroxysmal nocturnal hemoglobinuria (PNH) since its approval. However, its biweekly dosing regimen remains…”
Get full text

SARS-CoV-2 Infection in a patient with paroxysmal nocturnal haemoglobinuria (PNH) Treated with ravulizumab: a case report by Estival, Pablo, Colás, Blanca, Dai, Yang, Gonzalez, F. Ataulfo

“…The clinical course of a Paroxysmal Nocturnal Hemoglobinuria (PNH) patient receiving treatment with terminal complement by ravulizumab and SARS-CoV2 infection…”
Get full text

Interference of Hemoglobin (Hb) Hope on Measurement of HbA1c Using an HPLC Method by Lorenzo-Medina, Mercedes, De-La-Iglesia, Silvia, Ropero, Paloma, Nogueira-Salgueiro, Patricia, González-Fernández, F.Ataulfo

Get full text

Improving safety in blood transfusion using failure mode and effect analysis by Mora, Asunción, Ayala, Luis, Bielza, Rafael, Ataúlfo González, F., Villegas, Ana

“…BACKGROUND One of the medical areas where errors can have more serious consequences is the process of blood transfusion. We used failure mode and effect…”
Get full text

One‐year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab by Kulasekararaj, Austin G., Hill, Anita, Langemeijer, Saskia, Wells, Richard, González Fernández, F. Ataúlfo, Gaya, Anna, Ojeda Gutierrez, Emilio, Piatek, Caroline I., Mitchell, Lindsay, Usuki, Kensuke, Bosi, Alberto, Brodsky, Robert A., Ogawa, Masayo, Yu, Ji, Ortiz, Stephan, Röth, Alexander, Lee, Jong Wook, Peffault de Latour, Régis

“…Ravulizumab every 8 weeks showed non‐inferiority to eculizumab every 2 weeks in a 26‐week, phase 3, randomized controlled trial in adults with paroxysmal…”
Get full text

High incidence of the CD8/9 (+G) beta 0-thalassemia mutation in Spain by Villegas, A, Ropero, P, Ataulfo Gonzalez, F, Marti, E, Anguita, E, de Blas, JM

“…Departamento de Hematologia y Hemoterapia, Hospital Universitario San Carlos, Madrid, Spain. BACKGROUND AND OBJECTIVE: In Spain, as in other Mediterranean…”
Get full text

Late relapse in BCR/ABL-positive patients after non-intensive chemotherapy by Anguita, E, Ataulfo González, F, del Potro, E, Villegas, A

Get full text

Autosomal Recessive Congenital Dyserythropoietic Anemia Type III Is Caused By Mutations in the Centralspindlin RACGAP1 Component by Romero-Cortadellas, Lídia, Hernández, Gonzalo, Ferrer-Cortès, Xènia, Venturi, Veronica, Olivella, Mireia, Pérez de Soto, Concepción, Morales-Camacho, Rosario M., Villegas, Ana, Gonzalez-Fernandez, F. Ataulfo, Morado, Marta, Pérez-Montero, Santiago, Tornador, Cristian, Sánchez, Mayka

“…▪ An autosomal dominant form of congenital dyserythropoietic anemia type III (CDA III) is caused by a missense mutation in the KIF23 gene whose protein…”
Get full text

Patient preferences and quality of life implications of ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria by Peipert, John Devin, Kulasekararaj, Austin G, Gaya, Anna, Langemeijer, Saskia M. C, Yount, Susan, Gonzalez-Fernandez, F. Ataulfo, Ojeda Gutierrez, Emilio, Martens, Christa, Sparling, Amy, Webster, Kimberly A, Cella, David, Tomazos, Ioannis, Ogawa, Masayo, Piatek, Caroline I, Wells, Richard, Sicre de Fontbrune, Flore, Röth, Alexander, Mitchell, Lindsay, Hill, Anita, Kaiser, Karen

“…Background Eculizumab has transformed management of paroxysmal nocturnal hemoglobinuria (PNH) since its approval. However, its biweekly dosing regimen remains…”
Get full text

Patient preferences and quality of life implications of ravulizumab by Peipert, John Devin, Kulasekararaj, Austin G, Gaya, Anna, Langemeijer, Saskia M. C, Yount, Susan, Gonzalez-Fernandez, F. Ataulfo, Ojeda Gutierrez, Emilio, Martens, Christa, Sparling, Amy, Webster, Kimberly A, Cella, David, Tomazos, Ioannis, Ogawa, Masayo, Piatek, Caroline I, Wells, Richard, Sicre de Fontbrune, Flore, Röth, Alexander, Mitchell, Lindsay, Hill, Anita, Kaiser, Karen

“…Background Eculizumab has transformed management of paroxysmal nocturnal hemoglobinuria (PNH) since its approval. However, its biweekly dosing regimen remains…”
Get full text

One-Year Efficacy and Safety from a Phase 3 Trial of Ravulizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Receiving Prior Eculizumab Treatment by Kulasekararaj, Austin, Hill, Anita, Langemeijer, Saskia, Wells, Richard A., Gonzalez-Fernandez, F. Ataulfo, Gaya, Anna, Ojeda Gutierrez, Emilio, Piatek, Caroline I., Mitchell, Lindsay D, Usuki, Kensuke, Bosi, Alberto, Brodsky, Robert A., Ogawa, Masayo, Yu, Ji, Ortiz, Stephan, Röth, Alexander, Lee, Jong-Wook, Peffault de Latour, Régis

“…INTRODUCTION Ravulizumab, an innovative long-acting C5 complement inhibitor, was recently approved in the United States, Europe, and Japan for the treatment of…”
Get full text

Results from a Phase 3, Multicenter, Non-Inferiority Study of Ravulizumab (ALXN1210) Versus Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Currently Treated with Eculizumab by Kulasekararaj, Austin G., Hill, Anita, Rottinghaus, Scott T., Langemeijer, Saskia, Wells, Richard A., Gonzalez-Fernandez, F. Ataulfo, Gaya, Anna, Lee, Jong-Wook, Ojeda Gutierrez, Emilio, Piatek, Caroline I., Szer, Jeffrey, Risitano, Antonio M., Nakao, Shinji, Bachman, Eric, Shafner, Lori, Damokosh, Andrew I., Ortiz, Stephan, Röth, Alexander, Peffault De Latour, Regis

“…▪ Introduction Ravulizumab, an innovative complement C5 inhibitor given every 8 weeks (q8w), was recently demonstrated in a large phase 3 study of patients…”
Get full text

Identification of the Hb Lepore phenotype by HPLC by Ropero, P, Gonzalez, FA, Sanchez, J, Anguita, E, Asenjo, S, Del Arco, A, Murga, MJ, Ramos, R, Fernandez, C, Villegas, A

“…Servicio de Hematologia y Hemoterapia, Hospital Clinico San Carlos, Madrid, Spain. BACKGROUND AND OBJECTIVE: Hb Lepore is a structurally abnormal hemoglobin in…”
Get full text

C-->T mutation at -158 G gamma HPFH associated with 4 bp deletion (-225-222) in the promoter region of the A gamma gene in homozygous beta 0 39 nonsense thalassemia by Ataulfo Gonzalez, F, Ropero, P, Sánchez, J, Rosatellí, C, Galanello, R, Villegas, A

Get full text

Homozygous Constant Spring : the first case described in the West by NOGUERA, N. I, ATAULFO GONZALEZ, F, ROPERO, P, ANGUITA, E, MILANI, A. C, VILLEGAS, A

Get full text

A new polymorphism (G→A) in the ψζ1 globin gene by VILLEGAS, Ana, ANGUITA, Eduardo, NOGUERA, Nélida, ATAULFO GONZALEZ, Fernando, ROPERO, Paloma, SANCHEZ, Jesus, MILANI, Angela Cristina, ESPINOS, Domingo, BOWDEN, Don, HIGGS, Douglas

Get full text

C-->T mutation at -158 G gamma HPFH associated with 4 bp deletion (-225-222) in the promoter region of the A gamma gene in homozygous beta 0 39 nonsense thalassemia by Ataulfo Gonzalez, F, Ropero, P, Sánchez, J, Rosatellí, C, Galanello, R, Villegas, A

Get full text

Detection of bcr/abl mRNA in a case of chronic myelogenous leukemia in long-term remission: CML or sensitivity of detection? by Anguita, E, Villegas, A, Diaz-Mediavilla, J, Gonzalez, FA, del Potro, E, Espinos, D

“…Department of Haematology, Hospital Universitario San Carlos, Madrid, Spain. Chronic myelogenous leukemia (CML) is a myelo-proliferative disorder which, after…”
Get full text

Acute promyelocytic leukemia relapse in the central nervous system during hematologic and molecular remission by Anguita, Eduardo, Villegas, Ana, González, F. Ataulfo, Díaz‐Mediavilla, Joaquín, Lo Coco, Francesco

Get full text